Contact the Editorial Desk

Editorial correspondence

The correspondence that helps most is about the record: a citation quoted wrong, a newer DSIP or Semax study that belongs on the references page, or a fix to how a finding is described. A note that sharpens the accuracy or currency of these pages is the most useful thing that arrives here, and each one gets a careful read.

The submissions we can act on quickest name the page, quote the passage in question, and attach a supporting reference — a DOI or PubMed ID where possible — so the change can be checked before it is made.

Editorial mailbox: editors@chaipeptide.com

What this desk cannot do

To spare anyone a wasted message: this is a plain-language reader, not a clinical service and not a product vendor, so it cannot counsel or endorse human use of DSIP or Semax, cannot suggest a dose or schedule for any individual, cannot judge whether an animal or lab finding fits a particular person's situation, and cannot help find, source, or buy either compound from any supplier.

DSIP and Semax are not FDA-approved in the United States; Semax is a registered prescription drug only in Russia and Ukraine. For medical guidance, consult a licensed clinician where you live. Replies are not guaranteed and may be slow; the mailbox is checked only intermittently.